Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Paul Bunn to Clinical Trials as Topic

This is a "connection" page, showing publications Paul Bunn has written about Clinical Trials as Topic.

 
Connection Strength
  
 
 
1.335
  
  1. Pacheco J, Bunn PA. Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133. Clin Lung Cancer. 2019 05; 20(3):148-160.e2.
    View in: PubMed
    Score: 0.116
  2. Hirsch FR, Suda K, Wiens J, Bunn PA. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016 Sep 03; 388(10048):1012-24.
    View in: PubMed
    Score: 0.099
  3. Doebele RC, Oton AB, Peled N, Camidge DR, Bunn PA. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer. 2010 Jul; 69(1):1-12.
    View in: PubMed
    Score: 0.062
  4. Bunn PA. Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors? J Clin Oncol. 2007 Jun 20; 25(18):2504-5.
    View in: PubMed
    Score: 0.052
  5. Solomon B, Bunn PA. Adjuvant chemotherapy for non-small cell lung cancer. Cancer Invest. 2007 Jun; 25(4):217-25.
    View in: PubMed
    Score: 0.052
  6. Dziadziuszko R, Hirsch FR, Varella-Garcia M, Bunn PA. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how? Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4409s-4415s.
    View in: PubMed
    Score: 0.049
  7. Solomon B, Bunn PA. Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent. Future Oncol. 2005 Dec; 1(6):733-46.
    View in: PubMed
    Score: 0.047
  8. Solomon B, Mitchell JD, Bunn PA. Adjuvant chemotherapy for resected non-small-cell lung cancer. Oncology (Williston Park). 2005 Nov; 19(13):1685-97; discussion 1698-700, 1705.
    View in: PubMed
    Score: 0.047
  9. Bunn PA. The potential role of proteasome inhibitors in the treatment of lung cancer. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4263s-4265s.
    View in: PubMed
    Score: 0.042
  10. Winterhalder RC, Hirsch FR, Kotantoulas GK, Franklin WA, Bunn PA. Chemoprevention of lung cancer--from biology to clinical reality. Ann Oncol. 2004 Feb; 15(2):185-96.
    View in: PubMed
    Score: 0.041
  11. Raben D, Helfrich B, Ciardiello F, Bunn PA. Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know. Lung Cancer. 2003 Aug; 41 Suppl 1:S15-22.
    View in: PubMed
    Score: 0.040
  12. Bunn PA, Shepherd FA, Sandler A, Le Chevalier T, Belani CP, Kosmidis PA, Scagliotti GV, Giaccone G. Ongoing and future trials of biologic therapies in lung cancer. Lung Cancer. 2003 Aug; 41 Suppl 1:S175-86.
    View in: PubMed
    Score: 0.040
  13. Simon GR, Bunn PA. Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments. Cancer Invest. 2003; 21(1):87-104.
    View in: PubMed
    Score: 0.038
  14. Niyikiza C, Hanauske AR, Rusthoven JJ, Calvert AH, Allen R, Paoletti P, Bunn PA. Pemetrexed safety and dosing strategy. Semin Oncol. 2002 Dec; 29(6 Suppl 18):24-9.
    View in: PubMed
    Score: 0.038
  15. Bunn PA. New targeted therapies for lung cancer: expectations and reality. MedGenMed. 2002 Aug 05; 4(3):12.
    View in: PubMed
    Score: 0.037
  16. Bunn PA. Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors). Semin Oncol. 2002 Jun; 29(3 Suppl 9):17-22.
    View in: PubMed
    Score: 0.037
  17. Calvert H, Bunn PA. Future directions in the development of pemetrexed. Semin Oncol. 2002 Apr; 29(2 Suppl 5):54-61.
    View in: PubMed
    Score: 0.036
  18. Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol. 2002 Feb; 29(1 Suppl 4):3-14.
    View in: PubMed
    Score: 0.036
  19. Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 4):37-46.
    View in: PubMed
    Score: 0.036
  20. Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA. HER2/neu expression in malignant lung tumors. Semin Oncol. 2002 Feb; 29(1 Suppl 4):51-8.
    View in: PubMed
    Score: 0.036
  21. Bunn PA. Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer. Semin Oncol. 1999 Feb; 26(1 Suppl 4):25-30.
    View in: PubMed
    Score: 0.029
  22. Bunn PA. Triplet chemotherapy combinations with new agents: is there a rationale? Semin Oncol. 1998 Aug; 25(4 Suppl 9):55-61.
    View in: PubMed
    Score: 0.028
  23. Bunn PA. Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-153-S12-162.
    View in: PubMed
    Score: 0.026
  24. Bunn PA, Carney DN. Overview of chemotherapy for small cell lung cancer. Semin Oncol. 1997 Apr; 24(2 Suppl 7):S7-69-S7-74.
    View in: PubMed
    Score: 0.026
  25. Bunn PA. Combination paclitaxel and platinum in the treatment of lung cancer: US experience. Semin Oncol. 1996 Dec; 23(6 Suppl 15):9-15.
    View in: PubMed
    Score: 0.025
  26. Bunn PA. Future directions in clinical research for lung cancer. Chest. 1994 Dec; 106(6 Suppl):399S-407S.
    View in: PubMed
    Score: 0.022
  27. Bunn PA. The treatment of non-small cell lung cancer: current perspectives and controversies, future directions. Semin Oncol. 1994 Jun; 21(3 Suppl 6):49-59.
    View in: PubMed
    Score: 0.021
  28. Bunn P, Arriagada R, Choi N, Feld R, Gregor A, Jett J, Johnson B, Komaki R, Kristjansen P, Murray N, et al. Combined modality therapy in small cell lung cancer. Lung Cancer. 1994 Mar; 10 Suppl 1:S25-8.
    View in: PubMed
    Score: 0.021
  29. Bunn PA, Norris DA. The therapeutic role of interferons and monoclonal antibodies in cutaneous T-cell lymphomas. J Invest Dermatol. 1990 Dec; 95(6 Suppl):209S-212S.
    View in: PubMed
    Score: 0.017
  30. Bunn PA, Lichter AS, Makuch RW, Cohen MH, Veach SR, Matthews MJ, Anderson AJ, Edison M, Glatstein E, Minna JD, et al. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer. A prospective, randomized trial. Ann Intern Med. 1987 May; 106(5):655-62.
    View in: PubMed
    Score: 0.013
  31. Foon KA, Bunn PA. Alpha-interferon treatment of cutaneous T cell lymphoma and chronic lymphocytic leukemia. Semin Oncol. 1986 Dec; 13(4 Suppl 5):35-9.
    View in: PubMed
    Score: 0.013
  32. Bunn PA, Greco FA, Einhorn L. Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer. Semin Oncol. 1986 Sep; 13(3 Suppl 3):45-53.
    View in: PubMed
    Score: 0.012
  33. Lynch TJ, Adjei AA, Bunn PA, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, J?nne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4365s-4371s.
    View in: PubMed
    Score: 0.012
  34. Foon KA, Schroff RW, Bunn PA. Clinical applications of monoclonal antibodies for patients with leukemia and lymphoma. Prog Clin Biol Res. 1986; 211:265-84.
    View in: PubMed
    Score: 0.012
  35. Morstyn G, Schechter GP, Ihde DC, Carney DN, Eddy JL, Cohen MH, Minna JD, Bunn PA. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness. Cancer Treat Rep. 1984 Dec; 68(12):1439-46.
    View in: PubMed
    Score: 0.011
  36. Lynch TJ, Adjei AA, Bunn PA, DuBois RN, Gandara DR, Giaccone G, Govindan R, Herbst RS, Johnson BE, Khuri FR, Perez-Soler R, Rosell R, Rowinsky EK, Sandler AB, Scagliotti GV, Schiller JH, Shapiro GI, Socinski MA, Hart CS. Novel agents in the treatment of lung cancer: conference summary statement. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4199s-4204s.
    View in: PubMed
    Score: 0.011
  37. Hirsch FR, Bunn PA, Johnson DH, Giaccone G, Rosell R. Lung cancer. Introduction. Lung Cancer. 2003 Aug; 41 Suppl 1:S1.
    View in: PubMed
    Score: 0.010
  38. Hirsch FR, Bunn PA, Dmitrovsky E, Field JK, Franklin WA, Greenberg RE, Hansen HH, Henschke CI, Rigas JR, Smith RA, Toennesen P, Mulshine JL. IV international conference on prevention and early detection of lung cancer, Reykjavik, Iceland, August 9-12, 2001. Lung Cancer. 2002 Sep; 37(3):325-44.
    View in: PubMed
    Score: 0.009
  39. Agus DB, Bunn PA, Franklin W, Garcia M, Ozols RF. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol. 2000 Dec; 27(6 Suppl 11):53-63; discussion 92-100.
    View in: PubMed
    Score: 0.008
  40. Bunn PA, Ihde DC, Cohen MH, Shackney SE, Minna JD. Streptozotocin in advanced small cell bronchogenic carcinoma: an ineffective nonmyelosuppressive agent. Cancer Treat Rep. 1978 Mar; 62(3):479-81.
    View in: PubMed
    Score: 0.007
  41. Roth MS, Bunn PA, Foon KA. Interferon therapy for lymphoproliferative disorders. Cancer Treat Res. 1988; 38:231-52.
    View in: PubMed
    Score: 0.003
  42. Seifter EJ, Bunn PA, Cohen MH, Makuch RW, Dunnick NR, Javadpour N, Bensimon H, Eddy JL, Minna JD, Ihde DC. A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate. J Clin Oncol. 1986 Sep; 4(9):1365-73.
    View in: PubMed
    Score: 0.003
  43. Lichter AS, Bunn PA, Ihde DC, Cohen MH, Makuch RW, Carney DN, Johnston-Early A, Minna JD, Glatstein E. The role of radiation therapy in the treatment of small cell lung cancer. Cancer. 1985 May 01; 55(9 Suppl):2163-75.
    View in: PubMed
    Score: 0.003
  44. Brower M, Ihde DC, Johnston-Early A, Bunn PA, Cohen MH, Carney DN, Makuch RW, Matthews MJ, Radice PA, Minna JD. Treatment of extensive stage small cell bronchogenic carcinoma. Effects of variation in intensity of induction chemotherapy. Am J Med. 1983 Dec; 75(6):993-1000.
    View in: PubMed
    Score: 0.003
  45. Bleehen NM, Bunn PA, Cox JD, Dombernowsky P, Fox RM, H?st H, Joss R, White JE, Wittes RE. Role of radiation therapy in small cell anaplastic carcinoma of the lung. Cancer Treat Rep. 1983 Jan; 67(1):11-9.
    View in: PubMed
    Score: 0.002
  46. Minna JD, Bunn PA, Carney DN, Cohen MH, Cuttita F, Fosieck BE, Gazdar AF, Ihde DC, Johnston-Early A, Matthews MJ, Makuch R, Oie H, Rosen S, Lichter A, Glatstein E. Experience of the National Cancer Institute (USA) in the treatment and biology of small cell lung cancer. Bull Cancer. 1982; 69(1):83-93.
    View in: PubMed
    Score: 0.002
  47. Cohen MH, Makuch R, Johnston-Early A, Ihde DC, Bunn PA, Fossieck BE, Minna JD. Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Cancer Treat Rep. 1981 Mar-Apr; 65(3-4):187-95.
    View in: PubMed
    Score: 0.002
  48. Radice PA, Bunn PA, Ihde DC. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies. Cancer Treat Rep. 1979 Aug; 63(8):1231-9.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)